Nikolai Naryshkin
Company: Ribonaut Therapeutics
Job title: Chief Scientific Officer
Seminars:
Emerging Modalities Beyond Splice Modulation: Harnessing Covalent Binders, Proximity-Inducing Compounds & lncRNA Targets to Discover Functional RNA Binders 1:00 pm
While splice modulation has paved the way for RNA-targeted therapeutics, the next frontier lies in unlocking the therapeutic potential of directly targeting RNA. This workshop explores innovative strategies exploring covalently binding RNA, bivalent compounds inducing proximity between RNA and effector molecules, and the untapped opportunity of targeting long non-coding RNAs. Attendees will cover: • Exploring…Read more
day: Pre Conference workshop day
Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma 9:00 am
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics • How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines • How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets…Read more
day: Conference Day Two